AMTX
NASD Aemetis, Inc.$1.46 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.46, $0.08 below the day’s high of $1.54
- YTD change
- +5.04%
- vs 20-day SMA
- -17.64%
- vs 200-day SMA
- -26.35%
Price ranges
Price & Performance
-0.81 (-35.68%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 94.7% away from all-time highs of $27.44
- AMTX is up 5% since the beginning of the year
- AMTX is down 49% over the past 12 months
- AMTX is down 22% over the past 1 month
- 12% of all AMTX investors are betting against AMTX
AMTX reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -46.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.03
- Last 5 days
- -15.61%
- vs 8-day SMA
- -9.91%
No alerts for AMTX in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Aemetis, Inc. is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota. The India segment refers to the Kakinada plant, administrative offices in Hyderabad, and holding companies in Nevada and Mauritius. Its products include glycerin, ethanol, food and feed, biodiesel, and edible oils. The company was founded by Eric Armstrong McAfee in 2006 and is headquartered in Cupertino, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.